Monitoring of acute migraine attacks: Placebo response and safety data

Headache

Volumn 38, Issue 1, 1998, Pages 35-38

  Jhee, Stanford S ^a   Salazar, Daniel E ^b   Ford, Neville F ^b   Fulmor, I Edgar ^b   Sramek, John J ^a   Cutler, Neal R ^a,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE   (United States)

Author keywords

Ambulatory electrocardiography; Clinical trials; Headache; Migraine; Placebo

Indexed keywords

DIHYDROERGOTAMINE; METHYSERGIDE; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PAIN ASSESSMENT; PRIORITY JOURNAL; SINUS BRADYCARDIA; TREATMENT OUTCOME;

EID: 0031892585     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3801035.x     Document Type: Article

References (15)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
2. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol. 1991;238(suppl 1):S38-S44.
3. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993;43(suppl 3):S16-S20.
4. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159-177.
5. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin. 1990;8:829-839.
6. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45(suppl 7):S5-S9.
7. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology. 1995;45(suppl 7):S15-S20.
8. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995;45(suppl 7):S10-S14.
9. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45:1505-1509.
10. Cutler NR, Claghorn J, Sramek JJ, et al. Pilot study of MK-462 in migraine. Cephalalgia. 1996;16:113-116.
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
12. Fleiss JL. Statistical Methods for Rates and Proportions. New York: Wiley; 1981:14-15.
13. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346:923-926.
14. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996;46:522-526.
15. Haring HP, Aichner F. Hemodynamic findings in migraine patients on transcranial Doppler sonography. Wien Klin Wochenschr. 1992;104:620-625.